Measuring the effects of therapy in parkinson disease [4]

JAMA

Volumn 291, Issue 20, 2004, Pages 2430-2431

  Shults, Clifford W ^a   Haas, Richard ^a   Oakes, David ^b   Kieburtz, Karl ^c   Plumb, Sandra ^c   Shoulson, Ira ^c   Beal, M Flint ^d   Juncos, Jorge ^e   Nutt, John ^f   Olanow, C Warren ^g   Schapira, Anthony H V ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UBIDECARENONE; ANTIOXIDANT; ANTIPARKINSON AGENT; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; UBIQUINONE;

DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; LETTER; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; NEUROLOGIC EXAMINATION; NOTE;

ANTIOXIDANTS; ANTIPARKINSON AGENTS; HUMANS; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; UBIQUINONE;

EID: 2442686920     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.20.2431-a     Document Type: Letter

References (0)